| The status of paediatric medicines initiatives around the world-what has happened and what has not? | |
| | |
MedLine Citation:
|
PMID: 21732178 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: This review was conducted to examine the current status of paediatric medicines initiatives across the globe. METHODS: The authors made a non-systematic descriptive review of current world situation. RESULTS: Two regions, the United States (US) and the European Union (EU), and the World Health Organization (WHO) have introduced strong paediatric initiatives to improve children's health through improving access to better paediatric medicines. The experience from the US initiative indicates that it is possible to stimulate development and study of paediatric medicines and provide important new information for improvement of paediatric therapy. The early results from the EU initiative are similarly encouraging. In Canada, Japan, Australia and other developed countries, specific paediatric medicines initiatives have been less extensive and weaker, with modest results. Disappointingly, current evidence suggests that results from clinical trials outside the US often do not benefit children in the country in which the trials were largely conducted. Pharmaceutical companies that have derived a financial benefit commensurate with the cost of doing the paediatric trials in one country do not seem to be making the results of these trials available to all countries if there is no financial incentive to the company. The WHO campaign 'make medicines child size' has produced substantive accomplishments in building improved foundations to improve mechanisms that will enhance children's access to critical medicines in resource-limited settings. However, practically all of this work has been performed using an amalgamation of short-term funding from a variety of sources as opposed to a sustained, programmatic commitment. CONCLUSIONS: Although much still needs to be done, it's clear that with concerted efforts and appropriate resources, change is possible but slow. Retaining and fostering public and political interest in paediatric medicines is challenging, but pivotal for success. |
| | |
Authors:
|
Kalle Hoppu; Gabriel Anabwani; Facundo Garcia-Bournissen; Madlen Gazarian; Gregory L Kearns; Hidefumi Nakamura; Robert G Peterson; Shalini Sri Ranganathan; Saskia N de Wildt |
Related Documents
:
|
3440988 - An epidemiological study of digoxin prescribing in general practice. 20441578 - Social determinants of prescribed and non-prescribed medicine use. 12801118 - Extemporaneous (magistral) preparation of oral medicines for children in european hospi... 18426418 - A survey of the scope of therapeutic practice by uk optometrists and their attitudes to... 7441788 - Career counseling as experienced by practicing black ophthalmologists. 19423678 - Why look at an spc? |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-7-6 |
Journal Detail:
|
Title: European journal of clinical pharmacology Volume: - ISSN: 1432-1041 ISO Abbreviation: - Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-7-6 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1256165 Medline TA: Eur J Clin Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Hospital for Children and Adolescents and Dept. of Clinical Pharmacology, University of Helsinki and Poison Information Centre, Helsinki University Central Hospital, P.O. Box 790, 00029, Helsinki, Finland, kaarlo.hoppu@hus.fi. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose t...
Next Document: Evolution of the IL17 receptor family in chordates: a new subfamily IL17REL.